Hudson Bay Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Hudson Bay Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.53M	Sell	36,173 -73,065	-67%	-$6.38M	0.01%	671
2026 Q1	$9.17M	Buy	+109,238	New	+$6.33M	0.03%	337
2025 Q3	–	Sell	-115,425	Closed	-$2.15M	–	1362
2025 Q2	$2.15M	Buy	115,425 +40,425	+54%	+$758K	0.01%	774
2025 Q1	$1.36M	Buy	+75,000	New	+$1.65M	﹤0.01%	876
2024 Q2	–	Sell	-80,000	Closed	-$2.4M	–	819
2024 Q1	$2.4M	Buy	+80,000	New	+$1.74M	0.01%	427

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Hudson Bay Capital Management's DNTH Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its Dianthus Therapeutics (DNTH) stake by 67% in Q2 2026, selling an estimated $6.38M and leaving 36,173 shares worth $3.53M. The position accounts for 0.01% of the portfolio, ranked #671.

Hudson Bay Capital Management first reported a position in DNTH in Q1 2024 and has held it in 5 quarters since. The position peaked at $9.17M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Hudson Bay Capital Management held 36,173 shares of Dianthus Therapeutics worth $3.53M as of Q2 2026.
Hudson Bay Capital Management sold 73,065 Dianthus Therapeutics shares in Q2 2026, an estimated $6.38M.
Dianthus Therapeutics made up 0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #671 holding.
Hudson Bay Capital Management first reported a position in Dianthus Therapeutics in Q1 2024 and has held it in 5 quarters since.
Hudson Bay Capital Management's Dianthus Therapeutics position peaked at $9.17M in Q1 2026.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.